COTELLIC

COTELLIC is used to treat a type of skin cancer called melanoma that has spread to other parts of the body and cannot be removed by surgery. COTELLIC is used in combination with another medicine called ZELBORAF® (containing the active ingredient vemurafenib).

Cotellic (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

The recommended dosage regimen of COTELLIC is 60 mg (three 20 mg tablets) orally taken once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity [see Clinical Studies (14)]. Take COTELLIC with or without food [see Clinical Pharmacology (12.3)].

Cobimetinib is also used to treat histiocytic neoplasms (conditions that cause an overproduction and accumulation of a type of white blood cell in parts of the body). Cobimetinib is in a class of medications called kinase inhibitors.

Mechanism of Action Cotellic (cobimetinib) is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal related kinase (ERK) pathway, which promotes cellular proliferation.

skin rash.joint, muscle, or bone pain.feeling tired or weak.liver injury.fever.nausea.itching.swelling of legs or arms.

Both cobimetinib and trametinib are used to inhibit BRAFV600E/K-mediated MEK1 activation, phospho-MEK1 activity, cellular phosphorylation of ERK, and cellular proliferation. Both inhibitors display anticancer activity against metastatic melanoma carrying the BRAF V600E/K mutation.

Cladribine is a disease modifying therapy (DMT) for relapsing MS. Its brand name is Mavenclad and you take it as a tablet.

Cobimetinib is a MEK inhibitor approved for the treatment of advanced melanoma and inhibits the cell viability of other types of cancer cells.

Penicillamine, sold under the brand name of Cuprimine among others, is a medication primarily used for the treatment of Wilson’s disease. It is also used for people with kidney stones who have high urine cystine levels, rheumatoid arthritis, and various heavy metal poisonings.

Everolimus is a type of targeted cancer drug. It is also known as Afinitor. It is a treatment for a number of different cancer types.

It is important to understand that cobimetinib and vemurafenib are not traditional chemotherapy drugs and have a different way of working. They work by targeting the cancer cells to stop them growing and spreading. The treatment schedule below explains how the drugs for this treatment are given.

COBIMETINIB (koe bi me ti nib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat certain types of melanoma, a skin cancer. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

Cotellic (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

Cobimetinib binds to phosphorylated MEK (with a 100x greater potency for MEK1 over MEK2) whilst trametinib binds to non-phosphorylated MEK1 and 2 with similar potencies, though both inhibit downstream ERK signalling.

Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma. Cobimetinib is a MEK inhibitor. Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech.

An oncologist may also be called a cancer specialist. The field of oncology has 3 major areas based on treatments: medical oncology, radiation oncology, and surgical oncology. Medical oncologists treat cancer using medication, including chemotherapy, immunotherapy, and targeted therapy.

Medical oncologists. These healthcare providers treat cancer using chemotherapy, hormonal therapies, immunotherapy and other targeted treatments. People often think of the medical oncologist as their primary cancer doctor. Most medical oncologists also specialize in hematology.

Different types are used to treat different cancers. For example, alkylating agents are commonly used to treat leukemia and lymphoma.

It includes medical oncology (the use of chemotherapy, hormone therapy, and other drugs to treat cancer), radiation oncology (the use of radiation therapy to treat cancer), and surgical oncology (the use of surgery and other procedures to treat cancer).

The cost for Cotellic oral tablet 20 mg is around $8,346 for a supply of 63 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

MEK inhibitorReported ocular side effectsPimasertib (MSC1936369, AS703026)Retinal vein occlusion, serous retinal detachment, macular edema and visual disturbancesCobimetinib (GDC-0973, XL-518, RG7421)Subfoveal neurosensory retinal detachment

Key takeaways: Mounjaro (tirzepatide) is a prescription medication that’s FDA approved to treat Type 2 diabetes. Without insurance, the average monthly cost of Mounjaro is between $1,000 to $1,200, depending on the pharmacy.

Following oral administration of COTELLIC 60 mg once daily in cancer patients, the mean elimination half-life (t1/2) was 44 (range: 23–70) hours.

Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma. Cobimetinib is a MEK inhibitor. Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech.

The cost for Definity intravenous suspension ((lipid microspheres)) is around $1,476 for a supply of 8 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Sotyktu Prices, Coupons and Patient Assistance Programs. Sotyktu (deucravacitinib) is a member of the multikinase inhibitors drug class and is commonly used for Plaque Psoriasis. The cost for Sotyktu oral tablet 6 mg is around $6,890 for a supply of 30 tablets, depending on the pharmacy you visit.

The cost for Vabysmo intravitreal solution (svoa 6 mg/0.05 mL) is around $2,316 for a supply of 0.05 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

The cost for Elahere intravenous solution (gynx 100 mg/20 mL) is around $6,690 for a supply of 20 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

QuantityPer unitPrice5 milliliters$3.59$17.9416.7 milliliters$2.26$37.6925 milliliters$2.07$51.7050 milliliters$1.31 – $1.88$65.60 – $93.89

The cost for saxagliptin oral tablet 2.5 mg is around $454 for a supply of 30 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Cost. This medication very expensive (>$15,000 per bottle) but is available through an Orphan Drugs on Site Program (consignment-like program).

Genentech: Cotellic® (cobimetinib) – Information for Patients.

Cotellic (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

On November 10, 2015, cobimetinib (Cotellic; Genentech) received FDA approval for use in combination with vemurafenib (Zelboraf; Genentech) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Cotellic (cobimetinib) was approved by FDA on November 10, 2015, and indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

The FDA has approved cobimetinib (Cotellic) for the treatment of adult patients with histiocytic neoplasms. The FDA has approved cobimetinib (Cotellic) for the treatment of adult patients with histiocytic neoplasms, which include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis.

Cobimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

Dabrafenib and trametinib are targeted therapies: treatments that attack cancer cells with a specific gene or protein change. Dabrafenib targets cells with certain BRAF mutations and prevents the altered BRAF protein from sending growth signals. Trametinib blocks the activity of proteins that help send these signals.

Cancer researchers are developing new ways to treat advanced melanoma with greater success for patients. Targeted therapy is a new, effective treatment option that can shrink cancer cells and tumors and help patients with melanoma live longer.

Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Genentech: Zelboraf® (vemurafenib) – Information for Healthcare Providers.